---
id: antimicrobials_fluoroquinolone-generations_024
category: antimicrobials
tags: [antimicrobials, fluoroquinolones, generations, spectrum, ciprofloxacin, levofloxacin, moxifloxacin]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Fluoroquinolone Generations and Spectrum

**Q:** How are fluoroquinolones classified by generation, and what is the spectrum of each generation?

**A:**

**Classification by Generations:**

| **Generation** | **Agents** | **Spectrum** | **Clinical Use** |
|----------------|------------|--------------|------------------|
| **1st Generation** | Nalidixic acid | Gram-negatives (narrow) | UTI only (obsolete) |
| **2nd Generation** | **Ciprofloxacin**, **Levofloxacin**, Ofloxacin | Gram-negatives (excellent) + atypicals | UTI, GI, respiratory, Pseudomonas |
| **3rd Generation** | **Levofloxacin** (some classify as 2nd) | Enhanced Gram-positive (Strep pneumo) + above | CAP, HAP |
| **4th Generation** | **Moxifloxacin**, Gemifloxacin | Anaerobes + enhanced Gram-positive | Aspiration, intra-abdominal |

**Key Comparative Points:**
- **Ciprofloxacin:** BEST Pseudomonas coverage (MIC 2-8x lower than levo/moxi)
- **Levofloxacin:** Balanced Gram-negative and Gram-positive (respiratory FQ)
- **Moxifloxacin:** Enhanced anaerobic + Gram-positive, **NO Pseudomonas**

**Spectrum Progression:**
- **1st gen:** Narrow Gram-negative (UTI)
- **2nd gen:** ↑ Gram-negative + atypicals (Mycoplasma, Chlamydia, Legionella)
- **3rd gen:** ↑ Gram-positive (Strep pneumo)
- **4th gen:** ↑ Anaerobes

**Mnemonic: "Cipro Pseudomonas, Levo Lungs, Moxi Mouth (anaerobes)"**
- **Cipro** = Pseudomonas (best GNR)
- **Levo** = Lungs (respiratory, balanced)
- **Moxi** = Mouth (anaerobes, aspiration)

**Clinical Pearl:**
- **Ciprofloxacin:** Poor Strep pneumo coverage (not for CAP as monotherapy)
- **Moxifloxacin:** Poor Pseudomonas coverage (don't use for HAP with Pseudomonas risk)

**Media:** None

**Sources:** [AAFP 2000 - Quinolone classification], [StatPearls 2024], [CDC Emerging Infectious Diseases 2003], [UK MHRA 2024 - Systemic FQ restrictions]
